Complete remission^[*] achieved by steroid pulse therapy following rituximab treatment in a case with autoimmune haemorrhaphilia due to anti-factor XIII antibodies

 

^* Note: In this manuscript complete remission is defined as the disappearance of all anti-FXIII autoantibodie.

^† Both YN and AI contributed to this research project as senior authors.

• References

• 1 Kohler HP. et al. Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-1406.
• 2 Egbring R. et al. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Haemost 1996; 22: 419-425.
• 3 Ichinose A. Haemorrhagic acquired factor XIII (13) deficiency and acquired haemorrhaphilia 13 revisited. Semin Thromb Haemost 2011; 37: 382-388.
• 4 Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-370.
• 5 Pardos-Gea J. et al. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study. Haemophilia 2012; 18: 789-793.
• 6 Sakai M. et al. Successful steroid pulse treatment in childhood acquired haemophilia with nephrotic syndrome. Haemophilia 2005; 11: 285-289.
• 7 Narukawa N. et al. A case of factor VIII inhibitor-positive acquired haemophilia treated by plasmapheresis. Ther Apher 1999; 3: 323-325.
• 8 Mohri H. et al. Effective immunosuppresive therapies including steroid pulse treatment for intramuscular hematoma in iliopsoas in acquired haemophilia. Rinsho Ketsueki 2007; 48: 1544-1548.
• 9 Ushiki M. et al. Acquired haemophilia A with rectus abdominis muscle and intrapelvic hematomas after aortic arch replacement. Rinsho Ketsueki 2011; 52: 8-13.
• 10 Kohro J. et al. A case with SLE complicated with coagulation factor XIII deficiency. Ryumachi. 1997; 37: 326 [abstract in Japanese]
• 11 Kessel R. et al. A child with acquired factor XIII deficiency: case report and literature review. Haemophilia 2013; 19: 814-826.
• 12 Collins P. et al. EACH2 registry collaborators. Immunosuppression for acquired haemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47-55.
• 13 Sack FN. et al. Efficacy of rituximab in acquired factor XIII inhibitor after arterial rFVIIa-induced thrombosis. Haemophilia 2013; 19: e93-e94.
• 14 Boehlen F. et al. Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013; 109: 479-487.
• 15 Tha MH, Tien SL. Acquired factor XIII deficiency: still a clinical challenge in the era of novel therapy. Haemophilia 2014; 20: e104-e105.
• 16 Miesbach W. Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 2005; 93: 1001-1003.